Is Core Laboratories, Inc. overvalued or undervalued?

As of 21 November 2025, the valuation grade for Core Laboratories, Inc. moved from expensive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued, with a P/E ratio of 21, which is higher than the peer average of 22.72, and an EV to EBITDA ratio of 10.54, compared to its peer average of 11.61. Additionally, the Price to Book Value stands at 2.08, suggesting that the stock is trading at a premium relative to its book value.
In terms of peer comparison, while Core Laboratories has a lower EV to EBITDA than its peer average, its overall valuation metrics indicate that it is not aligned with the market's expectations for growth and profitability. The stock has underperformed significantly against the S&P 500, with a YTD return of -14.96% compared to the index's 12.26%, and a 3-year return of -28.27% versus 67.17% for the S&P 500, reinforcing the notion that the stock is overvalued in the current market environment.